New ways to repurpose salmeterol in an animal model of fibromyalgia

Mena Z. Shafiek,Hala F. Zaki,Ahmed F. Mohamed
DOI: https://doi.org/10.1111/fcp.13041
2024-11-06
Fundamental and Clinical Pharmacology
Abstract:Background Fibromyalgia (FM) is a syndrome of pervasive chronic pain accompanied by low mood, sleep disorders, and cognitive decline. The dysfunction of central pain processing systems along with neurotransmitter disturbances are possible contributing mechanisms. Genetic polymorphism of the β2 adrenergic receptors is reported in FM patients. It is reported that chronic β2 agonists administration is effective for neuropathic pain alleviation. No current information, however, exists on their potential to alleviate nociplastic pain, such as FM. Therefore, the purpose of the current study is to examine salmeterol's potential antiallodynic effects in experimentally produced FM and explore some of the possible contributing mechanisms. Methods Thirty rats are allocated into three groups (n = 10): a normal group, a reserpine group that received reserpine (1 mg/kg; s.c.) for 3 days, and a reserpine + salmeterol group that received salmeterol (1 mg/kg; i.p.) for 21 consecutive days following last reserpine injection. Results Reserpine administration resulted in behavioral and biochemical changes consistent with FM, including thermal and mechanical hyperalgesia, depressive behavior, and motor incoordination. This is coupled with disturbed spinal monoamine levels, depressed cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling, disturbed mitochondrial function/dynamics, and compromised blood‐nerve barrier integrity. Treatment with salmeterol conceivably reversed these effects. Conclusion β2 receptor agonists such as salmeterol could be regarded as a promising strategy for the management of FM.
pharmacology & pharmacy
What problem does this paper attempt to address?